- CODEN : IAJPBB
- issn 2349-7750
TITLE:
EVALUATION OF THE CLINICAL IMPACTS OF ERYTHROMYCIN AND AZITHROMYCIN IN THE TREATMENT OF THE CHILDREN SUFFERING FROM MYCOPLASMA PNEUMONIA
AUTHORS:
Dr Muhammad Amar Ali Aziz, Dr Muhammad Imtiaz Ullah, Dr Muhammad Irfan
ABSTRACT:
Objective: To compare and evaluate the clinical impacts of erythromycin and azithromycin in the treatment of the children suffering from mycoplasma pneumonia (MPP). Methodology: A sum of 122 children who were suffering from mycoplasma pneumonia and got admission in Bahawal Victoria Hospital Bahawalpur from December 2018 to November 2019 were the participants of this research work. We divided all the patients into two groups; observation group (OG) and control group (CG) with the application of the method of random number table, sixty-six patients in each group. The treatment of patients of the observation group was carried out with the use of azithromycin, where patients of the control group underwent treatment with erythromycin. Therapeutic impact, the prevalence of the adverse reactions and total duration of the disappearance of the symptoms were compared between the observation group and control group. Results: Rate of the efficacy of the observation group was 98.040%, and that of the control group was 74.510%; this Difference was significant statistically (X2=7.1840, P=0.0070). The rate of prevalence of adverse reactions in the patients of the observation group was 15.690%, much lower as compared to the patients of the control group (41.180%) (X2=6.3760, P=0.0020). The time of disappearance of rale, cough, fever and X-ray shadow of the patients of observation group was much short as compared to the patients of the control group, and this disparity was also significant statistically (P<0.050). Conclusion: Azithromycin is highly effective for the treatment of mycoplasma pneumonia among children as compared to the treatment with erythromycin. Azithromycin can further decrease the time for improvement in clinical signs and symptoms. There are only a few adverse reactions of this drug with high safety rate. KEYWORDS: Azithromycin, Symptoms, Observation
FULL TEXT
Approved Journal
NLM ID:101711216 [Serial]
Included in EuroPub database
ICV 2015 - 61.16
Indexed In
S.J Impact Factor:7.157
cosmos Impact Factor:4.153
ICMJE Recommendations
IP Indexing Impact Factor: 2.76
Cover Page
